Genomic instability-derived plasma extracellular vesicle-microRNA signature as a minimally invasive predictor of risk and unfavorable prognosis in breast cancer

[1]  A. Venkitaraman,et al.  Pulsatile MAPK Signaling Modulates p53 Activity to Control Cell Fate Decisions at the G2 Checkpoint for DNA Damage , 2020, Cell reports.

[2]  Raghu Kalluri,et al.  The biology, function, and biomedical applications of exosomes , 2020, Science.

[3]  Ahmedin Jemal,et al.  Breast cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[4]  Xing Li,et al.  MiR-421 Is Overexpressed and Promotes Cell Proliferation in Non-Small Cell Lung Cancer , 2019, Medical Principles and Practice.

[5]  P. Li,et al.  Evaluation of circulating small extracellular vesicles derived miRNAs as biomarkers of early colon cancer: a comparison with plasma total miRNAs , 2019, Journal of extracellular vesicles.

[6]  K. Khanna,et al.  Mechanisms of Genomic Instability in Breast Cancer. , 2019, Trends in molecular medicine.

[7]  N. Waddell,et al.  Patterns of Genomic Instability in Breast Cancer. , 2019, Trends in pharmacological sciences.

[8]  Eric P. Winer,et al.  Breast Cancer Treatment: A Review , 2019, JAMA.

[9]  Y. Shiloh,et al.  UBQLN4 Represses Homologous Recombination and Is Overexpressed in Aggressive Tumors , 2019, Cell.

[10]  A. Borovečki,et al.  The frequencies of micronuclei, nucleoplasmic bridges and nuclear buds as biomarkers of genomic instability in patients with urothelial cell carcinoma , 2018, Scientific Reports.

[11]  Jian Shen,et al.  MicroRNA-421-targeted PDCD4 regulates breast cancer cell proliferation , 2018, International journal of molecular medicine.

[12]  W. Yuan,et al.  Effect of exosomal miRNA on cancer biology and clinical applications , 2018, Molecular Cancer.

[13]  Sahar Ahmad,et al.  Science in Focus: Genomic Instability and its Implications for Clinical Cancer Care. , 2018, Clinical oncology (Royal College of Radiologists (Great Britain)).

[14]  I. MacRae,et al.  Regulation of microRNA function in animals , 2018, Nature Reviews Molecular Cell Biology.

[15]  Ashton C. Berger,et al.  Genomic and Functional Approaches to Understanding Cancer Aneuploidy. , 2018, Cancer cell.

[16]  F. Slack,et al.  MicroRNA therapeutics: towards a new era for the management of cancer and other diseases , 2017, Nature Reviews Drug Discovery.

[17]  N. Wu,et al.  RbAp48, a novel inhibitory factor that regulates the transcription of human immunodeficiency virus type 1. , 2016, International journal of molecular medicine.

[18]  T. Ochiya,et al.  Novel combination of serum microRNA for detecting breast cancer in the early stage , 2016, Cancer science.

[19]  Yong Peng,et al.  The role of MicroRNAs in human cancer , 2016, Signal Transduction and Targeted Therapy.

[20]  R. Gregory,et al.  MicroRNA biogenesis pathways in cancer , 2015, Nature Reviews Cancer.

[21]  Mary Helen Barcellos-Hoff,et al.  New tricks for an old fox: Impact of TGFβ on the DNA damage response and genomic stability , 2014, Science Signaling.

[22]  H. Ling,et al.  MicroRNAs, Genomic Instability and Cancer , 2014, International journal of molecular sciences.

[23]  G. Calin,et al.  MiR-200a regulates epithelial to mesenchymal transition-related gene expression and determines prognosis in colorectal cancer patients , 2014, British Journal of Cancer.

[24]  Hui Zhou,et al.  starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein–RNA interaction networks from large-scale CLIP-Seq data , 2013, Nucleic Acids Res..

[25]  M. Fabbri,et al.  MicroRNAs and other non-coding RNAs as targets for anticancer drug development , 2013, Nature Reviews Drug Discovery.

[26]  Ç. Gerçel-Taylor,et al.  The origin, function, and diagnostic potential of RNA within extracellular vesicles present in human biological fluids , 2013, Front. Genet..

[27]  P. Tan,et al.  Identification of Circulating MicroRNA Signatures for Breast Cancer Detection , 2013, Clinical Cancer Research.

[28]  N. Schultz,et al.  Cancer cells preferentially lose small chromosomes , 2013, International journal of cancer.

[29]  Carlos Caldas,et al.  Analysis of circulating tumor DNA to monitor metastatic breast cancer. , 2013, The New England journal of medicine.

[30]  D. Cleveland,et al.  Chromoanagenesis and cancer: mechanisms and consequences of localized, complex chromosomal rearrangements , 2012, Nature Medicine.

[31]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[32]  M. Campone,et al.  Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study , 2012, Breast Cancer Research.

[33]  Wei Zhang,et al.  Principles of microRNA involvement in human cancers , 2011 .

[34]  Carme Camps,et al.  microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. , 2011, Cancer research.

[35]  G. Calin,et al.  MicroRNAs in body fluids—the mix of hormones and biomarkers , 2011, Nature Reviews Clinical Oncology.

[36]  Min Liu,et al.  MicroRNA-372 Is Down-regulated and Targets Cyclin-dependent Kinase 2 (CDK2) and Cyclin A1 in Human Cervical Cancer, Which May Contribute to Tumorigenesis* , 2011, The Journal of Biological Chemistry.

[37]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[38]  Zhiyuan Shen.  Genomic instability and cancer: an introduction. , 2011, Journal of molecular cell biology.

[39]  W. Filipowicz,et al.  The widespread regulation of microRNA biogenesis, function and decay , 2010, Nature Reviews Genetics.

[40]  T. Halazonetis,et al.  Genomic instability — an evolving hallmark of cancer , 2010, Nature Reviews Molecular Cell Biology.

[41]  R. Gatti,et al.  ATM is down-regulated by N-Myc–regulated microRNA-421 , 2010, Proceedings of the National Academy of Sciences.

[42]  M. Barbacid,et al.  Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.

[43]  R. Bast,et al.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  R. Bast,et al.  American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer. , 2007, Journal of oncology practice.

[45]  P. Jeggo,et al.  The impact of a negligent G2/M checkpoint on genomic instability and cancer induction , 2007, Nature Reviews Cancer.

[46]  Mariette Schrier,et al.  A Genetic Screen Implicates miRNA-372 and miRNA-373 As Oncogenes in Testicular Germ Cell Tumors , 2006, Cell.

[47]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[48]  O. Sieber,et al.  Genomic instability — the engine of tumorigenesis? , 2003, Nature Reviews Cancer.

[49]  G. Ruvkun,et al.  Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans , 1993, Cell.

[50]  V. Ambros,et al.  The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 , 1993, Cell.

[51]  A. Amon,et al.  Context is everything: aneuploidy in cancer , 2019, Nature Reviews Genetics.

[52]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[53]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[54]  Anderson.  Principles of microRNA involvement in human cancers , 2011 .

[55]  Guohui Wan,et al.  Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway. , 2010, Cancer research.

[56]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[57]  Reuven Agami,et al.  A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. , 2006, Cell.

[58]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[59]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.